Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.

PHASE4UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Upadacitinib

15 mg po daily

DRUG

Adalimumab

40 mg sc every other week